TLX1 and acute lymphoblastic leukemia: Since HOX11-expressing malignancies are associated with deregulation of the G2/M cell cycle checkpoint [24-27] and chromosome missegregation [28,29], pharmacological inhibition of cyclin B1 could provide a specific intervention for the treatment of T-ALL.